Antimicrobial activity of LY163892, an orally administered 1-carbacephem.
LY163892 was found to be similar to cefaclor and slightly superior to cephalexin in antimicrobial activity and spectrum. Bacteria with MIC50 less than or equal to 8.0 mg/l included Escherichia coli, Klebsiella spp., Proteus mirabilis, Citrobacter diversus, Haemophilus influenzae, Branhamella catarrhalis, pathogenic Neisseria spp., oxacillin-susceptible staphylococci, and Streptococcus spp. Strains that produced plasmid-mediated beta-lactamases generally remained susceptible to LY163892. LY163892 was found to be bactericidal in general, but its MICs for some bacterial strains were adversely affected by increased inocula.
Jones
R N
RN
Clinical Microbiology Institute, Tualatin, Oregon 97062.
Barry
A L
AL
D001419:Bacteria / Q000187:drug effects*; D002433:Cefaclor / Q000494:pharmacology; D002506:Cephalexin / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests
D002511:Cephalosporins; C026739:carbacephems; C054920:loracarbef; D002433:Cefaclor; D002506:Cephalexin